Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Dec 15;2015(12):CD009898.
doi: 10.1002/14651858.CD009898.pub3.

Extracorporeal photopheresis versus alternative treatment for chronic graft-versus-host disease after haematopoietic stem cell transplantation in paediatric patients

Marcus Weitz  1 , Brigitte Strahm, Joerg J Meerpohl, Maria Schmidt, Dirk Bassler
Affiliations

Extracorporeal photopheresis versus alternative treatment for chronic graft-versus-host disease after haematopoietic stem cell transplantation in paediatric patients

Marcus Weitz et al. Cochrane Database Syst Rev. .

Update in

Abstract

Background: Chronic graft-versus-host disease (GvHD) is a major cause of morbidity and mortality after haematopoietic stem cell transplantation occurring in 6% to 65% of the recipients. Currently, the therapeutic mainstay for chronic GvHD are corticosteroids that are frequently combined with other immunosuppressive agents in people with steroid-refractory manifestations. There is no established standard treatment for steroid-refractory chronic GvHD. The therapeutic options for these patients include extracorporeal photopheresis (ECP), an immunomodulatory treatment that involves ex vivo collection of mononuclear cells from peripheral blood, exposure to the photoactive agent 8-methoxypsoralen, ultraviolet radiation and re-infusion of the processed cell product. The mechanisms of action of ECP are not completely understood. This is an updated version of a Cochrane review first published in 2014.

Objectives: To evaluate the effectiveness and safety of ECP for the management of chronic GvHD in children and adolescents after haematopoietic stem cell transplantation.

Search methods: We searched the Cochrane Register of Controlled Trials (CENTRAL) (Issue 9, 2015), MEDLINE and EMBASE databases from their inception to 23 September 2015. We searched the reference lists of potentially relevant studies without any language restriction. We searched eight trial registers and five conference proceedings on 29 September 2015.

Selection criteria: Randomised controlled trials (RCTs) comparing ECP with or without alternative treatment versus alternative treatment alone in paediatric patients with chronic GvHD after haematopoietic stem cell transplantation.

Data collection and analysis: Two review authors independently performed the study selection. We resolved disagreements in the selection of trials by consultation with a third review author.

Main results: No additional studies were identified in this 2015 review update, in total leading to no studies meeting the criteria for inclusion in this review.

Authors' conclusions: The efficacy of ECP in the treatment of chronic GvHD in paediatric patients after haematopoietic stem cell transplantation based on RCTs cannot be evaluated since the original version of this review and the first review update found no RCTs. Current recommendations are based on retrospective or observational studies only. Thus, ideally, ECP should be applied in the context of controlled trials only. However, performing RCTs in this patient population will be challenging due to the limited number of patients, the variable disease presentation and the lack of well-defined response criteria. International collaboration, multicentre trials and appropriate funding for such trials will be needed. If treatment decisions based on clinical data are made in favour of ECP, patients should be carefully monitored for beneficial and harmful effects. In addition, efforts should be made to share this information with other clinicians, for example by setting up registries for paediatric patients that are treated with ECP.

PubMed Disclaimer

Conflict of interest statement

None.

Figures

1
1
Identification of potentially eligible studies.
2
2
Identification of potentially eligible studies for 2015 update.
See this image and copyright information in PMC

Update of

Similar articles

See all similar articles

Cited by

References

References to studies excluded from this review

Abu‐Dalle 2014 {published data only}
    1. Abu‐Dalle I, Reljic T, Nishihori T, Antar A, Bazarbachi A, Djulbegovic B, et al. Extracorporeal photopheresis in steroid‐refractory acute or chronic graft‐versus‐host disease: results of a systematic review of prospective studies. Biology of Blood and Marrow Transplantation 2014;20:1677‐86. - PubMed
Apisarnthanarax 2003 {published data only}
    1. Apisarnthanarax N, Donato M, Korbling M, Couriel D, Gajewski J, Giralt S, et al. Extracorporeal photopheresis therapy in the management of steroid‐refractory or steroid‐dependent cutaneous chronic graft‐versus‐host disease after allogeneic stem cell transplantation: feasibility and results. Bone Marrow Transplantation 2003;31(6):459‐65. - PubMed
Balda 1996 {published data only}
    1. Balda B, Konstantinov A, Starz H, Gneklow A, Heidemann P. Extracorporeal photochemotherapy as an effective treatment modality in chronic graft versus host disease. Journal of the European Academy of Dermatology and Venereology 1996;7:155‐62. - PubMed
Besnier 1997 {published data only}
    1. Besnier DP, Chabannes D, Mahe B, Mussini JM, Baranger TA, Muller JY, et al. Treatment of graft‐versus‐host disease by extracorporeal photochemotherapy: a pilot study. Transplantation 1997;64(1):49‐54. - PubMed
Biagi 2000 {published data only}
    1. Biagi E, Perseghin P, Buscemi F, Dassi M, Rovelli A, Balduzzi A. Effectiveness of extracorporeal photochemotherapy in treating refractory chronic graft‐versus‐host disease. Haematologica 2000;85(3):329‐30. - PubMed
Bisaccia 2011 {published data only}
    1. Bisaccia E, Palangio M, Gonzalez J. Long‐term extracorporeal photochemotherapy in a pediatric patient with refractory sclerodermatous chronic graft‐versus‐host disease. Transfusion and Apheresis Science 2011;45(2):187‐90. - PubMed
Bruserud 2014 {published data only}
    1. Bruserud O, Tvedt THA, Paulsen PQ, Ahmed AB, Gedde‐Dahl T, Tjonnfjord GE, et al. Extracorporeal photopheresis (photochemotherapy) in the treatment of acute and chronic graft versus host disease: i mmunological mechanisms and the results from clinical studies. Cancer Immunology, Immunotherapy 2014;63:757‐77. - PMC - PubMed
Child 1999 {published data only}
    1. Child FJ, Ratnavel R, Watkins P, Samson D, Apperley J, Ball J, et al. Extracorporeal photopheresis (ECP) in the treatment of chronic graft‐versus‐host disease (GVHD). Bone Marrow Transplantation 1999;23(9):881‐7. - PubMed
D'Incan 2000 {published data only}
    1. D'Incan M, Kanold J, Halle P, Lumley L, Souteyrand P, Demeocq F. Extracorporeal photopheresis as an alternative therapy for drug‐resistant graft versus host disease: three cases. Annales de Dermatologie et de Venereologie 2000;127(2):166‐70. - PubMed
Dall'Amico 1997 {published data only}
    1. Dall'Amico R, Rossetti F, Zulian F, Montini G, Murer L, Andreetta B, et al. Photopheresis in paediatric patients with drug‐resistant chronic graft‐versus‐host disease. British Journal of Haematology 1997;97(4):848‐54. - PubMed
Das‐Gupta 2014 {published data only}
    1. Das‐Gupta E, Greinix H, Jacobs R, Zhou L, Savani BN, Engelhardt BG, et al. Extracorporeal photopheresis as second‐line treatment for acute graft‐versus‐host disease: impact on six‐month freedom from treatment failure. Haematologica 2014;99:1746‐52. - PMC - PubMed
Dhir 2014 {published data only}
    1. Dhir S, Slatter M, Skinner R. Recent advances in the management of graft‐versus‐host disease. Archives of Disease of Childhood 2014;99:1150‐7. - PubMed
Flowers 2008 {published data only}
    1. Flowers ME, Apperley JF, Besien K, Elmaagacli A, Grigg A, Reddy V, et al. A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft‐versus‐host disease. Blood 2008;112(7):2667‐74. - PubMed
Foss 2003 {published data only}
    1. Foss FM. Extracorporeal photopheresis in the treatment of graft‐vs‐host disease. Journal of Cutaneous Medicine and Surgery 2003;7(4 Suppl):13‐7. - PubMed
Foss 2005 {published data only}
    1. Foss FM, DiVenuti GM, Chin K, Sprague K, Grodman H, Klein A, et al. Prospective study of extracorporeal photopheresis in steroid‐refractory or steroid‐resistant extensive chronic graft‐versus‐host disease: analysis of response and survival incorporating prognostic factors. Bone Marrow Transplantation 2005;35(12):1187‐93. - PubMed
Halle 2002 {published data only}
    1. Halle P, Paillard C, D'Incan M, Bordigoni P, Piguet C, Lumley L, et al. Successful extracorporeal photochemotherapy for chronic graft‐versus‐host disease in pediatric patients. Journal of Hematotherapy & Stem Cell Research 2002;11(3):501‐12. - PubMed
Jagasia 2013 {published data only}
    1. Jagasia M, Greinix H, Robin M, Das‐Gupta E, Jacobs R, Savani BN, et al. Extracorporeal photopheresis versus anticytokine therapy as a second‐line treatment for steroid‐refractory acute GVHD: a multicenter comparative analysis. Biology of Blood and Marrow Transplantation 2013;19:1129‐33. - PubMed
Kanold 2003 {published data only}
    1. Kanold J, Paillard C, Halle P, D'Incan M, Bordigoni P, Demeocq F. Extracorporeal photochemotherapy for graft versus host disease in pediatric patients. Transfusion and Apheresis Science 2003;28(1):71‐80. - PubMed
Kanold 2005 {published data only}
    1. Kanold J, Messina C, Halle P, Locatelli F, Lanino E, Cesaro S, et al. Update on extracorporeal photochemotherapy for graft‐versus‐host disease treatment. Bone Marrow Transplantation 2005;35(Suppl 1):S69‐71. - PubMed
Kanold 2007 {published data only}
    1. Kanold J, Merlin E, Halle P, Paillard C, Marabelle A, Rapatel C, et al. Photopheresis in pediatric graft‐versus‐host disease after allogeneic marrow transplantation: clinical practice guidelines based on field experience and review of the literature. Transfusion 2007;47(12):2276‐89. - PubMed
Looks 1996 {published data only}
    1. Looks A, Fuchs D, Rulke D, Lange D, Zintl F, Wollina U. Successful treatment of acute graft versus host disease after bone marrow transplantation in 16‐year old girl with extracorporeal photopheresis. Onkologie 1996;7:155‐62.
Messina 2003 {published data only}
    1. Messina C, Locatelli F, Lanino E, Uderzo C, Zacchello G, Cesaro S, et al. Extracorporeal photochemotherapy for paediatric patients with graft‐versus‐host disease after hematopoietic stem cell transplantation. British Journal of Haematology 2003;122(1):118‐27. - PubMed
Perotti 1999 {published data only}
    1. Perotti C, Torretta L, Viarengo G, Roveda L, Bernuzzi S, Carbone S, et al. Feasibility and safety of a new technique of extracorporeal photochemotherapy: experience of 240 procedures. Haematologica 1999;84(3):237‐41. - PubMed
Peters 2000 {published data only}
    1. Peters C, Minkov M, Gadner H, Klingebiel T, Vossen J, Locatelli F, et al. Statement of current majority practices in graft‐versus‐host disease prophylaxis and treatment in children. Bone Marrow Transplantation 2000;26(4):405‐11. - PubMed
Rossetti 1995 {published data only}
    1. Rossetti F, Zulian F, Dall'Amico R, Messina C, Montini G, Zacchello F. Extracorporeal photochemotherapy as single therapy for extensive, cutaneous, chronic graft‐versus‐host disease. Transplantation 1995;59(1):149‐51. - PubMed
Rossetti 1996 {published data only}
    1. Rossetti F, Dall'Amico R, Crovetti G, Messina C, Montini G, Dini G, et al. Extracorporeal photochemotherapy for the treatment of graft‐versus‐host disease. Bone Marrow Transplantation 1996;18(Suppl 2):175‐81. - PubMed
Salvaneschi 2001 {published data only}
    1. Salvaneschi L, Perotti C, Zecca M, Bernuzzi S, Viarengo G, Giorgiani G, et al. Extracorporeal photochemotherapy for treatment of acute and chronic GVHD in childhood. Transfusion 2001;41(10):1299‐305. - PubMed
Zecca 2000 {published data only}
    1. Zecca M, Locatelli F. Management of graft‐versus‐host disease in paediatric bone marrow transplant recipients. Paediatric Drugs 2000;2(1):29‐55. - PubMed

Additional references

Akpek 2001
    1. Akpek G, Lee SM, Anders V, Vogelsang GB. A high‐dose pulse steroid regimen for controlling active chronic graft‐versus‐host disease. Biology of Blood and Marrow Transplantation 2001;7(9):495‐502. - PubMed
Akpek 2003
    1. Akpek G, Lee SJ, Flowers ME, Pavletic SZ, Arora M, Lee S, et al. Performance of a new clinical grading system for chronic graft‐versus‐host disease: a multicenter study. Blood 2003;102(3):802‐9. - PubMed
Allan 2007
    1. Allan SE, Crome SQ, Crellin NK, Passerini L, Steiner TS, Bacchetta R, et al. Activation‐induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production. International Immunology 2007;19(4):345‐54. - PubMed
Arai 2010
    1. Arai S, Jagasia M, Storer B, Chai X, Pidala J, Cutler C, et al. Global and organ‐specific chronic graft‐versus‐host disease severity according to the 2005 NIH Consensus Criteria. Blood 2010;118(15):4242‐49. - PMC - PubMed
Atkinson 1990
    1. Atkinson K, Horowitz MM, Gale RP, Bekkum DW, Gluckman E, Good RA, et al. Risk factors for chronic graft‐versus‐host disease after HLA‐identical sibling bone marrow transplantation. Blood 1990;75(12):2459‐64. - PubMed
Barrett 2008
    1. Barrett AJ, Blanc K. Prophylaxis of acute GVHD: manipulate the graft or the environment?. Best Practice and Research. Clinical Haematology 2008;21(2):165‐76. - PMC - PubMed
Beredjiklian 1998
    1. Beredjiklian PK, Drummond DS, Dormans JP, Davidson RS, Brock GT, August C. Orthopaedic manifestations of chronic graft‐versus‐host disease. Journal of Pediatric Orthopedics 1998;18(5):572‐5. - PubMed
Bethea 1999
    1. Bethea D, Fullmer B, Syed S, Seltzer G, Tiano J, Rischko C, et al. Psoralen photobiology and photochemotherapy: 50 years of science and medicine. Journal of Dermatological Science 1999;19(2):78‐88. - PubMed
Billingham 1966
    1. Billingham RE. The biology of graft‐versus‐host reactions. Harvey Lectures 1966;62:21‐78. - PubMed
Bladon 2006
    1. Bladon J, Taylor PC. The down‐regulation of IL1alpha and IL6, in monocytes exposed to extracorporeal photopheresis (ECP)‐treated lymphocytes, is not dependent on lymphocyte phosphatidylserine externalization. Transplant International 2006;19(4):319‐24. - PubMed
Bolanos‐Meade 2008
    1. Bolanos‐Meade J, Vogelsang GB. Chronic graft‐versus‐host disease. Current Pharmaceutical Design 2008;14(20):1974‐86. - PubMed
Brickl 1984
    1. Brickl R, Schmid J, Koss FW. Clinical pharmacology of oral psoralen drugs. Photo‐dermatology 1984;1(4):174‐86. - PubMed
Bunin 2008
    1. Bunin NJ, Davies SM, Aplenc R, Camitta BM, DeSantes KB, Goyal RK, et al. Unrelated donor bone marrow transplantation for children with acute myeloid leukemia beyond first remission or refractory to chemotherapy. Journal of Clinical Oncology 2008;26(26):4326‐32. - PMC - PubMed
Busca 2000
    1. Busca A, Saroglia EM, Lanino E, Manfredini L, Uderzo C, Nicolini B, et al. Mycophenolate mofetil (MMF) as therapy for refractory chronic GVHD (cGVHD) in children receiving bone marrow transplantation. Bone Marrow Transplantation 2000;25(10):1067‐71. - PubMed
Cahn 2005
    1. Cahn JY, Klein JP, Lee SJ, Milpied N, Blaise D, Antin JH, et al. Prospective evaluation of 2 acute graft‐versus‐host (GVHD) grading systems: a joint Societe Francaise de Greffe de Moelle et Therapie Cellulaire (SFGM‐TC), Dana Farber Cancer Institute (DFCI), and International Bone Marrow Transplant Registry (IBMTR) prospective study. Blood 2005;106(4):1495‐500. - PMC - PubMed
Chosidow 1992
    1. Chosidow O, Bagot M, Vernant JP, Roujeau JC, Cordonnier C, Kuentz M, et al. Sclerodermatous chronic graft‐versus‐host disease. Analysis of seven cases. Journal of the American Academy of Dermatology 1992;26(1):49‐55. - PubMed
Cooke 2009
    1. Cooke K, Yanik G. Lung injury following hematopoietic cell transplantation. In: Appelbaum F, Forman S, Negrin R editor(s). Thomas' Hematopoietic Cell Transplantation. 4th Edition. Oxford: Wiley‐Blackwell, 2009:1456‐72.
Couriel 2006
    1. Couriel D, Carpenter PA, Cutler C, Bolanos‐Meade J, Treister NS, Gea‐Banacloche J, et al. Ancillary therapy and supportive care of chronic graft‐versus‐host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft‐versus‐host disease: V. Ancillary Therapy and Supportive Care Working Group report. Biology of Blood and Marrow Transplantation 2006;12(4):375‐96. - PubMed
Cutler 2006
    1. Cutler C, Miklos D, Kim HT, Treister N, Woo SB, Bienfang D, et al. Rituximab for steroid‐refractory chronic graft‐versus‐host disease. Blood 2006;108(2):756‐62. - PMC - PubMed
Dall'Amico 2002
    1. Dall'Amico R, Messina C. Extracorporeal photochemotherapy for the treatment of graft‐versus‐host disease. Therapeutic Apheresis 2002;6(4):296‐304. - PubMed
De Bueger 1993
    1. Bueger M, Bakker A, Bontkes H, Rood JJ, Goulmy E. High frequencies of cytotoxic T cell precursors against minor histocompatibility antigens after HLA‐identical BMT: absence of correlation with GVHD. Bone Marrow Transplantation 1993;11(5):363‐8. - PubMed
Deeks 2011
    1. Deeks J, Higgins J, Altman D. Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Diaconescu 2005
    1. Diaconescu R, Storb R. Allogeneic hematopoietic cell transplantation: from experimental biology to clinical care. Journal of Cancer Research and Clinical Oncology 2005;131(1):1‐13. - PubMed
Dudek 2003
    1. Dudek AZ, Mahaseth H, DeFor TE, Weisdorf DJ. Bronchiolitis obliterans in chronic graft‐versus‐host disease: analysis of risk factors and treatment outcomes. Biology of Blood and Marrow Transplantation 2003;9(10):657‐66. - PubMed
Eapen 2004
    1. Eapen M, Horowitz MM, Klein JP, Champlin RE, Loberiza FR Jr, Ringdén O, et al. the Histocompatibility and Alternate Stem Cell Source Working Committee of the International Bone Marrow Transplant Registry. Higher mortality after allogeneic peripheral‐blood transplantation compared with bone marrow in children and adolescents. Journal of Clinical Oncology 2004;22(24):4872‐80. - PubMed
Edelson 1987
    1. Edelson R, Berger C, Gasparro F, Jegasothy B, Heald P, Wintroub B, et al. Treatment of cutaneous T‐cell lymphoma by extracorporeal photochemotherapy. Preliminary results. New England Journal of Medicine 1987;316(6):297‐303. - PubMed
Ferrara 1991
    1. Ferrara JL, Deeg HJ. Graft‐versus‐host disease. New England Journal of Medicine 1991;324(10):667‐74. - PubMed
Ferrara 2004
    1. Ferrara JLM. Antin J. The pathophysiology of graft‐vs‐host disease. In: Blume KG, Forman SJ, Appelbaum FR editor(s). Thomas' Hematopoietic Cell Transplantation. 3rd Edition. Malden, MA: Blackwell Science, 2004:353‐68.
Filipovich 2005
    1. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft‐versus‐host disease: I. Diagnosis and Staging Working Group report. Biology of Blood and Marrow Transplantation 2005;11(12):945‐56. - PubMed
Fimiani 2004
    1. Fimiani M, Renzo M, Rubegni P. Mechanism of action of extracorporeal photochemotherapy in chronic graft‐versus‐host disease. British Journal of Dermatology 2004;150(6):1055‐60. - PubMed
Flowers 2002
    1. Flowers ME, Parker PM, Johnston LJ, Matos AV, Storer B, Bensinger WI, et al. Comparison of chronic graft‐versus‐host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long‐term follow‐up of a randomized trial. Blood 2002;100(2):415‐9. - PubMed
Flowers 2011
    1. Flowers ME, Inamoto Y, Carpenter PA, Lee SJ, Petersdorf EW, Pereira SE, et al. Comparative analysis of risk factors for acute and for chronic graft‐versus‐host‐disease according to National Institute of Health consensus criteria. Blood 2011;117(11):3214‐9. - PMC - PubMed
Fraser 2007
    1. Fraser CJ, Scott Baker K. The management and outcome of chronic graft‐versus‐host disease. British Journal of Haematology 2007;138(2):131‐45. - PubMed
Fujii 2008
    1. Fujii H, Cuvelier G, She K, Aslanian S, Shimizu H, Kariminia A, et al. Biomarkers in newly diagnosed pediatric‐extensive chronic graft‐versus‐host disease: a report from the Children's Oncology Group. Blood 2008;111(6):3276‐85. - PMC - PubMed
Gaziev 2010
    1. Gaziev J, Lucarelli G. Hematopoietic stem cell transplantation for thalassemia. Current Stem Cell Research and Therapy 2010;6(2):162‐9. - PubMed
Gilman 2000
    1. Gilman AL, Chan KW, Mogul A, Morris C, Goldman FD, Boyer M, et al. Hydroxychloroquine for the treatment of chronic graft‐versus‐host disease. Biology of Blood and Marrow Transplantation 2000;6(3A):327‐34. - PubMed
Gilman 2006
    1. Gilman AL, Serody J. Diagnosis and treatment of chronic graft‐versus‐host disease. Seminars in Hematology 2006;43(1):70‐80. - PubMed
Girardi 2002
    1. Girardi M, Schechner J, Glusac E, Berger C, Edelson R. Transimmunization and the evolution of extracorporeal photochemotherapy. Transfusion and Apheresis Science 2002;26(3):181‐90. - PubMed
Goldberg 2003
    1. Goldberg JD, Jacobsohn DA, Margolis J, Chen AR, Anders V, Phelps M, et al. Pentostatin for the treatment of chronic graft‐versus‐host disease in children. Journal of Pediatric Hematology/Oncology 2003;25(7):584‐8. - PubMed
Hackstein 2009
    1. Hackstein H, Misterek J, Nockher A, Reiter A, Bein G, Woessmann W. Mini buffy coat photopheresis for children and critically ill patients with extracorporeal photopheresis contraindications. Transfusion 2009;49(11):2366‐73. - PubMed
Heald 1989
    1. Heald P, Perez M, McKiernan G, Christiensen I, Edelson R. Extracorporeal photochemotherapy: indications, methodology, safety aspects, side effects and long‐term results. Photo‐dermatology 1989; Vol. 6, issue 4:171‐6. - PubMed
Heshmati 2003
    1. Heshmati F. Mechanisms of action of extracorporeal photochemotherapy. Transfusion and Apheresis Science 2003;29(1):61‐70. - PubMed
Higgins 2002
    1. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta‐analysis. Statistics in Medicine 2002;21(11):1539‐58. - PubMed
Higgins 2003
    1. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003;327(7414):557‐60. - PMC - PubMed
Higgins 2011
    1. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Higman 2004
    1. Higman MA, Vogelsang GB. Chronic graft versus host disease. British Journal of Haematology 2004;125(4):435‐54. - PubMed
Horowitz 2004
    1. Horowitz M. Uses and growth of hematopoietic cell transplantation. In: Forman J AF editor(s). Thomas' Hematopoietic Cell Transplantation. 3rd Edition. Malden, MA: Blackwell Science, 2004:9‐15.
Jacobsohn 2009
    1. Jacobsohn DA, Gilman AL, Rademaker A, Browning B, Grimley M, Lehmann L, et al. Pediatric Blood and Marrow Transplant Consortium study. Evaluation of pentostatin in corticosteroid‐refractory chronic graft‐versus‐host disease in children. Blood 2009;114(20):4354‐60. - PubMed
Jacobsohn 2010
    1. Jacobsohn DA. Optimal management of chronic graft‐versus‐host disease in children. British Journal of Haematology 2010;150(3):278‐92. - PubMed
Jagasia 2009
    1. Jagasia MH, Savani BN, Stricklin G, Engelhardt B, Kassim A, Dixon S, et al. Classic and overlap chronic graft‐versus‐host disease (cGVHD) is associated with superior outcome after extracorporeal photopheresis (ECP). Biology of Blood and Marrow Transplantation 2009; Vol. 15, issue 10:1288‐95. - PMC - PubMed
Janin 1994
    1. Janin A, Socie G, Devergie A, Aractingi S, Esperou H, Verola O, et al. Fasciitis in chronic graft‐versus‐host disease. A clinicopathologic study of 14 cases. Annals of Internal Medicine 1994; Vol. 120, issue 12:993‐8. - PubMed
Johnston 2005
    1. Johnston LJ, Brown J, Shizuru JA, Stockerl‐Goldstein KE, Stuart MJ, Blume KG, et al. Rapamycin (sirolimus) for treatment of chronic graft‐versus‐host disease. Biology of Blood and Marrow Transplantation 2005;11(1):47‐55. - PubMed
Kennedy‐Nasser 2006
    1. Kennedy‐Nasser AA, Leung KS, Mahajan A, Weiss HL, Arce JA, Gottschalk S, et al. Comparable outcomes of matched‐related and alternative donor stem cell transplantation for pediatric severe aplastic anemia. Biology of Blood and Marrow Transplantation 2006;12(12):1277‐84. - PubMed
Kjaergard 2001
    1. Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta‐analyses. Annals of Internal Medicine 2001;135(11):982‐9. - PubMed
Koc 2002
    1. Koc S, Leisenring W, Flowers ME, Anasetti C, Deeg HJ, Nash RA, et al. Therapy for chronic graft‐versus‐host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. Blood 2002;100(1):48‐51. - PubMed
Lamioni 2005
    1. Lamioni A, Parisi F, Isacchi G, Giorda E, Cesare S, Landolfo A, et al. The immunological effects of extracorporeal photopheresis unraveled: induction of tolerogenic dendritic cells in vitro and regulatory T cells in vivo. Transplantation 2005;79(7):846‐50. - PubMed
Lee 2003
    1. Lee SJ, Vogelsang G, Flowers ME. Chronic graft‐versus‐host disease. Biology of Blood and Marrow Transplantation 2003; Vol. 9, issue 4:215‐33. - PubMed
Legitimo 2007
    1. Legitimo A, Consolini R, Failli A, Fabiano S, Bencivelli W, Scatena F, et al. In vitro treatment of monocytes with 8‐methoxypsolaren and ultraviolet A light induces dendritic cells with a tolerogenic phenotype. Clinical and Experimental Immunology 2007;148(3):564‐72. - PMC - PubMed
Lin 2003
    1. Lin MT, Storer B, Martin PJ, Tseng LH, Gooley T, Chen PJ, et al. Relation of an interleukin‐10 promoter polymorphism to graft‐versus‐host disease and survival after hematopoietic‐cell transplantation. New England Journal of Medicine 2003;349(23):2201‐10. - PubMed
Lopez 2005
    1. Lopez F, Parker P, Nademanee A, Rodriguez R, Al‐Kadhimi Z, Bhatia R, et al. Efficacy of mycophenolate mofetil in the treatment of chronic graft‐versus‐host disease. Biology of Blood and Marrow Transplantation 2005;11(4):307‐13. - PubMed
Maeda 2005
    1. Maeda A, Schwarz A, Kernebeck K, Gross N, Aragane Y, Peritt D, et al. Intravenous infusion of syngeneic apoptotic cells by photopheresis induces antigen‐specific regulatory T cells. Journal of Immunology 2005;174(10):5968‐76. - PubMed
Martin 2008
    1. Martin PJ. Biology of chronic graft‐versus‐host disease: implications for a future therapeutic approach. The Keio Journal of Medicine 2008;57(4):177‐83. - PMC - PubMed
Martin 2009
    1. Martin PJ, Storer BE, Rowley SD, Flowers ME, Lee SJ, Carpenter PA, et al. Evaluation of mycophenolate mofetil for initial treatment of chronic graft‐versus‐host disease. Blood 2009;113(21):5074‐82. - PMC - PubMed
Meisel 2007
    1. Meisel R, Laws HJ, Balzer S, Bernbeck B, Kramm C, Schonberger S, et al. Comparable long‐term survival after bone marrow versus peripheral blood progenitor cell transplantation from matched unrelated donors in children with hematologic malignancies. Biology of Blood and Marrow Transplantation 2007;13(11):1338‐45. - PubMed
Melin‐Aldana 2007
    1. Melin‐Aldana H, Thormann K, Duerst R, Kletzel M, Jacobsohn DA. Hepatitic pattern of graft versus host disease in children. Pediatric Blood and Cancer 2007; Vol. 49, issue 5:727‐30. - PubMed
Miklos 2005
    1. Miklos DB, Kim HT, Miller KH, Guo L, Zorn E, Lee SJ, et al. Antibody responses to H‐Y minor histocompatibility antigens correlate with chronic graft‐versus‐host disease and disease remission. Blood 2005;105(7):2973‐8. - PMC - PubMed
Moher 1998
    1. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta‐analyses?. Lancet 1998;352(9128):609‐13. - PubMed
Mookerjee 1999
    1. Mookerjee B, Altomonte V, Vogelsang G. Salvage therapy for refractory chronic graft‐versus‐host disease with mycophenolate mofetil and tacrolimus. Bone Marrow Transplantation 1999;24(5):517‐20. - PubMed
Mutis 1999
    1. Mutis T, Gillespie G, Schrama E, Falkenburg JH, Moss P, Goulmy E. Tetrameric HLA class I‐minor histocompatibility antigen peptide complexes demonstrate minor histocompatibility antigen‐specific cytotoxic T lymphocytes in patients with graft‐versus‐host disease. Nature Medicine 1999;5(7):839‐42. - PubMed
Parmar 1998
    1. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta‐analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815‐34. - PubMed
Pavletic 2005
    1. Pavletic SZ, Carter SL, Kernan NA, Henslee‐Downey J, Mendizabal AM, Papadopoulos E, et al. Influence of T‐cell depletion on chronic graft‐versus‐host disease: results of a multicenter randomized trial in unrelated marrow donor transplantation. Blood 2005;106(9):3308‐13. - PMC - PubMed
Perotti 2010
    1. Perotti C, Fante C, Tinelli C, Viarengo G, Scudeller L, Zecca M, et al. Extracorporeal photochemotherapy in graft‐versus‐host disease: a longitudinal study on factors influencing the response and survival in pediatric patients. Transfusion 2010;50(6):1359‐69. - PubMed
Peters 2003
    1. Peters C, Steward CG. Hematopoietic cell transplantation for inherited metabolic diseases: an overview of outcomes and practice guidelines. Bone Marrow Transplantation 2003;31(4):229‐39. - PubMed
Przepiorka 1995
    1. Przepiorka D, Weisdorf D, Martin P, Klingemann H G, Beatty P, Hows J, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995;15:825‐8. - PubMed
Ram 2009
    1. Ram R, Gafter‐Gvili A, Yeshurun M, Paul M, Raanani P, Shpilberg O. Prophylaxis regimens for GVHD: systematic review and meta‐analysis. Bone Marrow Transplantation 2009;43(8):643‐53. - PubMed
Rappeport 2011
    1. Rappeport JM, O'Reilly RJ, Kapoor N, Parkman R. Hematopoietic stem cell transplantation for severe combined immune deficiency or what the children have taught us. Hematology/Oncology Clinics of North America 2011;25(1):17‐30. - PubMed
RevMan 2014 [Computer program]
    1. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Rocha 2000
    1. Rocha V, Wagner JE Jr, Sobocinski KA, Klein JP, Zhang MJ, Horowitz MM, et al. Eurocord and International Bone Marrow Transplant Registry Working Committee on Alternative Donor and Stem Cell Sources. Graft‐versus‐host disease in children who have received a cord‐blood or bone marrow transplant from an HLA‐identical sibling. New England Journal of Medicine 2000;342(25):1846‐54. - PubMed
Salmasian 2010
    1. Salmasian H, Rohanizadegan M, Banihosseini S, Rahimi Darabad R, Rabbani‐Anari M, Shakiba A, et al. Corticosteroid regimens for treatment of acute and chronic graft versus host disease (GvHD) after allogenic stem cell transplantation. Cochrane Database of Systematic Reviews 2010, Issue 1. [DOI: 10.1002/14651858.CD005565.pub2] - DOI - PMC - PubMed
Scarisbrick 2008
    1. Scarisbrick JJ, Taylor P, Holtick U, Makar Y, Douglas K, Berlin G, et al. U.K. consensus statement on the use of extracorporeal photopheresis for treatment of cutaneous T‐cell lymphoma and chronic graft‐versus‐host disease. British Journal of Dermatology 2008;158(4):659‐78. - PubMed
Schooneman 2003
    1. Schooneman F. Extracorporeal photopheresis technical aspects. Transfusion and Apheresis Science 2003;28(1):51‐61. - PubMed
Schulz 1995
    1. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408‐12. - PubMed
Shah 2007
    1. Shah AJ, Kapoor N, Crooks GM, Weinberg KI, Azim HA, Killen R, et al. The effects of Campath 1H upon graft‐versus‐host disease, infection, relapse, and immune reconstitution in recipients of pediatric unrelated transplants. Biology of Blood and Marrow Transplantation 2007;13(5):584‐93. - PubMed
Shimada 2005
    1. Shimada K, Yokozawa T, Atsuta Y, Kohno A, Maruyama F, Yano K, et al. Solid tumors after hematopoietic stem cell transplantation in Japan: incidence, risk factors and prognosis. Bone Marrow Transplantation 2005;36(2):115‐21. - PubMed
Shulman 1988
    1. Shulman HM, Sullivan KM. Graft‐versus‐host disease: allo‐ and autoimmunity after bone marrow transplantation. Concepts in Immunopathology 1988;6:141‐65. - PubMed
Smith 1998
    1. Smith EP, Sniecinski I, Dagis AC, Parker PM, Snyder DS, Stein AS, et al. Extracorporeal photochemotherapy for treatment of drug‐resistant graft‐vs.‐host disease. Biology of Blood and Marrow Transplantation 1998;4(1):27‐37. - PubMed
Sniecinski 1994
    1. Sniecinski I. Extracorporeal photochemotherapy: a scientific overview. Transfusion Science 1994;15(4):429‐37. - PubMed
Sterne 2011
    1. Sterne JAC, Egger M, Moher D. Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Stewart 2004
    1. Stewart BL, Storer B, Storek J, Deeg HJ, Storb R, Hansen JA, et al. Duration of immunosuppressive treatment for chronic graft‐versus‐host disease. Blood 2004;104(12):3501‐6. - PubMed
Storb 1986
    1. Storb R, Deeg HJ, Farewell V, Doney K, Appelbaum F, Beatty P, et al. Marrow transplantation for severe aplastic anemia: methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft‐versus‐host disease. Blood 1986;68(1):119‐25. - PubMed
Sullivan 1981
    1. Sullivan KM, Shulman HM, Storb R, Weiden PL, Witherspoon RP, McDonald GB, et al. Chronic graft‐versus‐host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood 1981;57(2):267‐76. - PubMed
Sullivan 1988a
    1. Sullivan KM, Witherspoon RP, Storb R, Deeg HJ, Dahlberg S, Sanders JE, et al. Alternating‐day cyclosporine and prednisone for treatment of high‐risk chronic graft‐v‐host disease. Blood 1988;72(2):555‐61. - PubMed
Sullivan 1988b
    1. Sullivan KM, Witherspoon RP, Storb R, Weiden P, Flournoy N, Dahlberg S, et al. Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft‐v‐host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. Blood 1988;72(2):546‐54. - PubMed
Sullivan 1991
    1. Sullivan KM, Agura E, Anasetti C, Appelbaum F, Badger C, Bearman S, et al. Chronic graft‐versus‐host disease and other late complications of bone marrow transplantation. Seminars in Hematology 1991;28(3):250‐9. - PubMed
Sullivan 2004
    1. Sullivan K. Graft‐versus‐host disease. In: Blume KG, Forman SJ, Appelbaum FR editor(s). Thomas Hematopoietic Cell Transplantation. 3rd Edition. Malden, MA: Blackwell Science, 2004:633‐64.
Szodoray 2010
    1. Szodoray P, Papp G, Nakken B, Harangi M, Zeher M. The molecular and clinical rationale of extracorporeal photochemotherapy in autoimmune diseases, malignancies and transplantation. Autoimmunity Reviews 2010;9(6):459‐64. - PubMed
Toubai 2008
    1. Toubai T, Sun Y, Reddy P. GVHD pathophysiology: is acute different from chronic?. Best Practice and Research. Clinical Haematology 2008;21(2):101‐17. - PubMed
Treister 2005
    1. Treister NS, Woo SB, O'Holleran EW, Lehmann LE, Parsons SK, Guinan EC. Oral chronic graft‐versus‐host disease in pediatric patients after hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation 2005;11(9):721‐31. - PubMed
Vogelsang 1992
    1. Vogelsang GB, Farmer ER, Hess AD, Altamonte V, Beschorner WE, Jabs DA, et al. Thalidomide for the treatment of chronic graft‐versus‐host disease. New England Journal of Medicine 1992;326(16):1055‐8. - PubMed
Vogelsang 2001
    1. Vogelsang GB. How I treat chronic graft‐versus‐host disease. Blood 2001;97(5):1196‐201. - PubMed
Voss 2010
    1. Voss CY, Fry TJ, Coppes MJ, Blajchman MA. Extending the horizon for cell‐based immunotherapy by understanding the mechanisms of action of photopheresis. Transfusion Medicine Reviews 2010;24(1):22‐32. - PubMed
Walters 2000
    1. Walters MC, Storb R, Patience M, Leisenring W, Taylor T, Sanders JE, et al. Impact of bone marrow transplantation for symptomatic sickle cell disease: an interim report. Multicenter investigation of bone marrow transplantation for sickle cell disease. Blood 2000;95(6):1918‐24. - PubMed
Walters 2005
    1. Walters MC. Stem cell therapy for sickle cell disease: transplantation and gene therapy. Hematology/the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2005;2005:66‐73. - PubMed
Williamson 2002
    1. Williamson PR, Smith CT, Hutton JL, Marson AG. Aggregate data meta‐analysis with time‐to‐event outcomes. Statistics in Medicine 2002;21(22):3337‐51. - PubMed
Wingard 2002
    1. Wingard JR, Vogelsang GB, Deeg HJ. Stem cell transplantation: supportive care and long‐term complications. Hematology/the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2002;2002:422‐44. - PubMed
Wolff 2011
    1. Wolff D, Schleuning M, Harsdorf S, Bacher U, Gerbitz A, Stadler M, et al. Consensus conference on clinical practice in chronic GVHD: second‐line treatment of chronic graft‐versus‐host disease. Biology of Blood and Marrow Transplantation 2011;17(1):1‐17. - PubMed
Xia 2009
    1. Xia CQ, Campbell KA, Clare‐Salzler MJ. Extracorporeal photopheresis‐induced immune tolerance: a focus on modulation of antigen‐presenting cells and induction of regulatory T cells by apoptotic cells. Current Opinion in Organ Transplantation 2009;14(4):338‐43. - PMC - PubMed
Yoo 1996
    1. Yoo EK, Rook AH, Elenitsas R, Gasparro FP, Vowels BR. Apoptosis induction of ultraviolet light A and photochemotherapy in cutaneous T‐cell lymphoma: relevance to mechanism of therapeutic action. Journal of Investigative Dermatology 1996;107(2):235‐42. - PubMed
Zecca 2002
    1. Zecca M, Prete A, Rondelli R, Lanino E, Balduzzi A, Messina C, et al. Chronic graft‐versus‐host disease in children: incidence, risk factors, and impact on outcome. Blood 2002;100(4):1192‐200. - PubMed
Zhang 2006
    1. Zhang C, Todorov I, Zhang Z, Liu Y, Kandeel F, Forman S, et al. Donor CD4+ T and B cells in transplants induce chronic graft‐versus‐host disease with autoimmune manifestations. Blood 2006;107(7):2993‐3001. - PubMed

References to other published versions of this review

Weitz 2012
    1. Weitz M, Strahm B, Meerpohl JJ, Bassler D. Extracorporeal photopheresis versus alternative treatment for chronic graft‐versus‐host disease after haematopoietic stem cell transplantation in paediatric patients. Cochrane Database of Systematic Reviews 2012, Issue 6. [DOI: 10.1002/14651858.CD009898] - DOI - PubMed
Weitz 2014
    1. Weitz M, Strahm B, Meerpohl JJ, Bassler D. Extracorporeal photopheresis versus alternative treatment for chronic graft‐versus‐host disease after haematopoietic stem cell transplantation in paediatric patients. Cochrane Database of Systematic Reviews 2014, Issue 2. [DOI: 10.1002/14651858.CD009898.pub2] - DOI - PubMed

Publication types

LinkOut - more resources